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Abstract
We here analyzed the prevalence of extra-thyroidal malignancies (EM) in 6,386 female pa-
tients affected by different thyroid disease (TD). At first, an age-matched analysis of EM in
all patients was performed. We then evaluated EM prevalence in four TD diagnostic catego-
ries: non-nodular TD (n = 2,159); solitary nodule (n = 905); multinodular TD (n = 2,871); dif-
ferentiated thyroid cancers (n = 451). Finally, patients were grouped based on the absence
(n = 3,820) or presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase (TPOAb)
(n = 2,369), or anti-Thyroid Stmulating Hormone (TSH) receptor autoantibodies (n = 197). A
total of 673 EM were recorded. EM prevalence in TD patients was higher compared to the
general population (Odds Ratio, OR 3.21) and the most frequent EM was breast cancer
(OR 3.94), followed by colorectal (OR 2.18), melanoma (OR 6.71), hematological (OR
8.57), uterus (OR 2.52), kidney (OR 3.40) and ovary (OR 2.62) neoplasms. Age-matched
analysis demonstrated that the risk of EM was maximal at age 0–44 yr (OR 11.28), remain-
ing lower, but significantly higher that in the general population, in the 45–59 and 60–74
year age range. Breast and hematological malignancies showed an increased OR in all TD,
while other cancers associated with specific TD. An increased OR for melanoma, breast
and hematological malignancies was observed in both TPOAb and/or TgAb autoantibody
negative and positive patients, while colorectal, uterus, kidney and ovary cancers showed
an increased OR only in thyroid autoantibody negative patients. In conclusions, women af-
fected by both benign and malignant TD, especially at a younger age and in absence of thy-
roid autoimmunity, have an increased risk of developing primary EM, thus requiring a
careful follow-up and surveillance.
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Introduction
Thyroid diseases are more frequent in females than in males [1]. Iodine deficiency is the
world’s most common cause of thyroid disease leading to hypothyroidism and diffuse or nodu-
lar goiter. In iodine-repleted areas thyroid autoimmunity, causing either chronic lymphocytic
thyroiditis or Graves’ disease, represents the main type of thyroid disease [1]. The prevalence
of nodular thyroid disease varies according to the diagnostic methods employed and the popu-
lations analyzed, being higher in areas with low iodine intake [1–4]. Although the majority of
thyroid nodules are benign tumors, about 5% of them harbors a malignant lesion derived from
the transformation of parafollicular cells or thyrocytes which generate medullary thyroid can-
cer (MTC) and well-differentiated thyroid cancer (DTC), respectively. The latter comprises the
papillary (PTC), which account for about 90% of all thyroid carcinomas, and follicular (FTC)
histotypes [5–6]. Despite the relevant progress made in the comprehension of the molecular
pathogenesis of both benign and malignant thyroid tumors, much more needs to be learned re-
garding their etiology [7–9]. To this regard, accumulated data drawn from large-scale case
studies documenting a 30% increase in the risk of a second primary thyroid cancer in patients
who have had other primary malignancies are of interest [10–13]. Correspondingly, a 20–42%
increased risk of second primary malignancies in patients affected by DTC has been reported
[14–21]. In particular, for some cancers (e.g. prostate, kidney and adrenal gland) the risk was
statistically higher within a year following the diagnosis of DTC, while for other cancers (e.g.
colon, rectum and breast) the risk increased with the duration of the follow-up [22]. Whether
the effects of treatments, environmental or genetic factors are responsible for the association
between DTC and other cancers, is still a matter of debate [10–13]. As to the prevalence of EM
in patients affected by benign thyroid disease, few and conflicting data have been reported,
mainly regarding breast cancer [23–27]. Herein, on the basis of a cross-sectional study of 6,386
female patients, we evaluated the association of benign and malignant thyroid disease with
other primary EM, compared to the general population of the same geographical area.
Patients and Methods
Case study
In this cross-sectional study we included 6,386 consecutive female patients (mean age 51.2 yr,
age range 18–92 yr) affected by various thyroid disease diagnosed according to standard crite-
ria [28–30] undergoing their first observation at the Thyroid Unit of the Umberto I Hospital of
Rome, Italy, between 2000 and 2011. All the patients came from central-southern Italy, an area
characterized by a moderate iodine deficiency [31]. Patients gave the written informed consent,
and their records were de-identified prior to the analysis. The ethics committee of the Umberto
I Hospital of Rome approved the study (n°. 2615/17.01.2013). Patients with MTC and those
with a less than one year follow-up were excluded from the case study. For each patient, age,
anti-thyroglobulin (TgAb), anti-thyroperoxidase (TPOAb), and anti-TSH receptor (TSHRAb)
autoantibodies, and the presence of one or more primary EM were recorded. Prevalence of EM
in the general population of the central-southern Italy was obtained from the relative regional
cancer registries [32]. At first, an age-matched analysis of EM in all the thyroid disease patients
concerned was performed (Table 1). Then, we evaluated EM prevalence in four thyroid disease
diagnostic categories, which included: 1) 2,159 patients with non-nodular thyroid disease
(NNTD) comprising chronic lymphocytic thyroiditis, non-autoimmune hypothyroidisms, and
Graves’ diseases; 2) 905 patients with solitary thyroid nodule (SN); 3) 2,871 patients with multi-
nodular thyroid disease (MNTD); 4) 451 patients affected by differentiated thyroid cancers
(DTC) (Table 2). Finally, the patients were divided into 3 groups based on the absence
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Table 1. Age and Extra-Thyroidal Malignancies in the 6,386 Female Patients Included in the Study.
Age range 0–44 45–59 60–74 >75 All






149 1,940 3,557 3,988 1,473
EM patient: expected/
observed
3.2/59 42.1/172 41.6/106 15.2/18 94.1/355
OR (95% CI) 18.747(13.581–
25.595)
4.354(3.689–5.135) 2.704(2.188–3.325) 1.197(0.701–1.922) 3.937(3.490–4.441)




17 270 1,015 1,964 447
EM patient: expected/
observed
0.4/3 5.8/23 11.9/28 7.5/8 28.5/62
OR (95% CI) 8.150(1.529–28.205) 3.959(2.462–6.081) 2.393(1.575–3.499) 1.073(0.459–2.141) 2.183(1.644–2.857)




52 169 231 255 127
EM patient: expected/
observed
1.1/15 3.7/18 2.7/15 0.9/6 8.1/54
OR (95% CI) 13.391(6.990–24.196) 4.943(2.856–8.071) 5.614(3.082–9.492) 6.275(2.267–
13.973)
6.707(4.779–9.303)




47 106 164 182 92
EM patient expected/
observed
1.0/24 2.3/9 1.9/15 0.7/2 5.9/50









16 227 771 1,018 287
EM patient: expected/
observed
0.3/13 4.9/16 9.0/13 3.9/4 18.3/46
OR (95% CI) 37.697(16.659–
83.680)
3.266(1.832–5.433) 1.447(0.765–2.500) 1.034(0.280–2.679) 2.521(1.803–3.455)




20 81 216 310 97
EM patient: expected/
observed
0.4/3 1.7/9 2.5/7 1.2/2 6.2/21
OR (95% CI) 6.927(1.317–23.382) 5.140(2.266–10.263) 2.783(1.103–5.850) 1.701(0.204–6.241) 3.398(2.012–5.493)




29 168 285 236 120
(Continued)
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(n = 3,820) or presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase (TPOAb)
(n = 2,369), or anti-TSH receptor (TSHRAb) autoantibodies (n = 197) (Table 3). Sixty-five low
frequency EM (with no more than 10 cases each) were grouped together and indicated as other
EM. These include cancer of: bladder (n = 10), lung (n = 9), cervix (n = 8), pancreas (n = 8),
stomach (n = 7), central nervous system (n = 5), liver (n = 5), larynx (n = 2), bone (n = 2), sar-
coma (n = 2), external genitals (n = 2), salivary gland (n = 1), gallbladder (n = 1), hepatopan-
creatic ampulla (n = 1), mesothelioma (n = 1) and ameloblastic cancer (n = 1). The
hematological malignancies included leukemia (n = 17), Hodgkin lymphoma (n = 13) and
non-Hodgkin lymphoma (n = 20).
Statistical analysis
The prevalence of each EM was determined for the patients taken as a whole or divided into
different sub-groups. The Chi square test, the Fisher exact test and the prevalence odds ratio
(OR) along with the 95% confidence interval (95% CI) were calculated to assess the association
between all categories of thyroid disease patients and EM using STATA, version 12 (College
Station, Texas, Stata Corporation). The prevalence odds ratio was used since, in this cross-sec-
tional study, it represents the best measure of the association between thyroid disease and
extra-thyroidal malignancies. The results were considered statistically significant when the
p value was<0.05.
Table 1. (Continued)
Age range 0–44 45–59 60–74 >75 All





0.6/4 3.6/7 3.3/6 0.9/3 7.7/20
OR (95% CI) 6.372(1.626–18.168) 1.924 (0.761–4.058) 1.805(0.656–3.989) 3.364(0.686–
10.024)
2.615(1.542–4.224)




14 49 101 168 48
EM patient: expected/
observed
0.3/12 1.1/24 1.2/25 0.6/4 3.1/65














576 3,893 8,111 10,602 3,544
EM patient: expected/
observed
12.5/133 84.4/278 94.8/215 40.3/47 226.3/673
OR (95% CI) 11.281(9.225–13.750) 3.629(3.180–4.141) 2.553(2.192–2.973) 1.190(0.857–1.620) 3.206(2.937–3.500)
P values <0.0001 <0.0001 <0.0001 0.2644 <0.0001
The total number of thyroid disease patients with extra-thyroidal cancer was 629, of whom 38 patients had two extra-thyroidal primary cancers and 3
patients had three extra-thyroidal cancers for a total of 673 malignancies. The general population prevalence values are referred per 100,000 persons,
from which the expected cases in the different patient’s groups were estimated.
doi:10.1371/journal.pone.0122958.t001
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Table 2. Thyroid Diseases, Age and Extra-Thyroidal Malignancies in the 6,386 Female Patients Included in the Study.
NNTD SN MNTD DTC All
N. of patients 2,159 905 2,871 451 6,386
Mean age (yr)±SD 47±15.4 50±14.7 55±13.9 48.2±14.5 51.2±15
Age range 18–91 18–85 18–89 18–92 18–92
Extra-thyroidal malignancies (prevalence in the general population/100,000)
Breast (1473)
expected/observed 31.8/73 13.3/48 42.3/209 6.6/25 94.1/355
OR (95% CI) 2.341(1.817–2.975) 3.746(2.728–5.038) 5.221(4.507–6.117) 3.925(2.504–5.898) 3.937(3.490–4.441)
P values <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Colorectal (447)
expected/observed 9.7/17 4/4 12.8/38 2.0/3 28.5/62
OR (95% CI) 1.760(1.014–2.857) 0.984(0.266–2.547) 2.974(2.073–4.156) 1.485(0.304–4.395) 2.183(1.644–2.857)
P values 0.0210 0.9749 <0.0001 0.4937 <0.0001
Melanoma (127)
expected/observed 2.7/13 1.1/6 3.6/33 0.6/2 8.1/54
OR (95% CI) 4.764(2.465–8.459) 5.249(1.886–11.784) 9.144(6.026–13.528) 3.503(0.418–12.983) 6.707(4.779–9.303)
P values <0.0001 <0.0001 <0.0001 0.1147 <0.0001
Hematological (92)
expected/observed 2/16 0.8/6 2.6/23 0.4/5 5.9/50
OR (95% CI) 8.108(4.441–13.906) 7.248(2.586–16.441) 8.770(5.290–13.995) 12.174(3.843–29.645) 8.570(5.942–12.236)
P values <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Uterus (287)
expected/observed 6.2/10 2.6/7 8.2/24 1.3/5 18.3/46
OR (95% CI) 1.617(0.766–3.022) 2.708(1.076–5.675) 2.923(1.843–4.555) 3.895(1.249–9.261) 2.521(1.803–3.455)
P values 0.1325 0.0069 <0.0001 0.0012 <0.0001
Kidney (97)
expected/observed 2.1/3 0.9/2 2.8/12 0.4/4 6.2/21
OR (95% CI) 1.433(0.290–4.318) 2.281(0.272–8.483) 4.328(2.157–7.911) 9.216(2.451–24.514) 3.398(2.012–5.493)
P values 0.5374 0.2356 <0.0001 <0.0001 <0.0001
Ovary (120)
expected/observed 2.6/6 1.1/0 3.4/11 0.5/3 7.7/20
OR (95% CI) 2.320(0.834–5.205) n.d. 3.201(1.555–5.944) 5.574(1.129–16.779) 2.615(1.542–4.224)
P values 0.0386 n.d. 0.0001 0.0010 <0.0001
Others EM (48)
expected/observed 1/18 0.4/8 1.4/36 0.2/3 3.1/65
OR (95% CI) 17.507(9.568–30.710) 18.571(7.564–39.736) 26.442(16.643–41.662) 13.944(2.768–43.515) 21.413(14.506–31.780)
P values <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
All (3544)
expected/observed 76.5/156 32.0/81 101.7/386 16.0/50 226.3/673
OR (95% CI) 2.120(1.788–2.511) 2.675(2.097–3.174) 4.228(3.772–4.738) 3.394(2.472–4.571) 3.206(2.937–3.500)
P values <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
NNTD, non-nodular thyroid disease; SN, solitary nodule; MNTD, multinodular thyroid disease; DTC, differentiated thyroid cancer; n.d., not determinable;
95% CI, 95% confidence interval. The expected cases in the different patient groups were estimated according to the prevalence of the different tumors
occurring in the general population.
doi:10.1371/journal.pone.0122958.t002
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Results
Prevalence of EM in thyroid disease patients
The prevalence of EM in the general population of central-southern Italy is 3,544/100,000
(3.5%) [32]. As described in Table 1, we analyzed 6,386 consecutive female patients affected by
various thyroid disease. Of the total, 629 (9.8%) patients showed EM, 38 of whom had two and
3 had three EM, which brought the total EM count to 673. Of these, 489 had been diagnosed
before (range 2–41 yr, median 5 yr), 97 simultaneously (within 1 year before or after), and 87
after (2–36 yr, median 4 yr) being diagnosed with thyroid disease. The most frequently encoun-
tered EM was breast cancer with 355 cases (52.75% of all EM), followed by colorectal cancer
with 62 cases (9.21%), melanoma with 54 cases (8.02%), hematological malignancies with 50
cases (7.43%), cancer of the uterus with 46 cases (6.84%), kidney cancer with 21 cases (3.12%)
and ovary cancer with 20 cases (2.97%). The overall prevalence of EM in thyroid disease pa-
tients is significantly (OR 3.21, p<0.0001) greater than that recorded for the general population
(see last column of Table 1).
Age-matched association of thyroid disease and EM
The age-matched analysis demonstrated that the risk of EM was maximal for the 0–44 yr age
range, with an OR of 11.28 (p<0.0001), spanning from 6.37 for ovary cancer to 37.70 for can-
cer of the uterus (Table 1 and Fig 1). The OR for all EM remains significantly (p<0.0001)
higher for the 45–59 yr and 60–74 yr age ranges, being 3.63 and 2.55, respectively. In patients
older than 75, with the exception of melanoma, the OR for EM (OR 1.19) was not significantly
different from that of the general population (Table 1).
Table 3. Prevalence of Extra-Thyroidal Malignancies in Patients Positive (n = 2,369) or Negative (n = 3,820) for TgAb and/or TPOAb.
Extra-thyroidal
malignancies









Breast 102 3.010 (2.428–
3.711)
<0.0001 246 6.604 (3.996–
5.303)
<0.0001
Colorectal 15 1.419 (0.786–
2.371)
0.1815 45 2.655 (1.906–
3.619)
<0.0001
Melanoma 19 6.358 (3.700–
10.364)
<0.0001 35 7.272 (4.846–
10.661)
<0.0001
Hematological 21 9.713 (5.731–
15.764)
<0.0001 28 8.012 (5.049–
12.374)
<0.0001
Uterus 9 1.325 (0.600–
2.555)
0.4052 36 3.305 (2.266–
4.693)
<0.0001
Kidney 2 0.870 (0.104–
3.231)
0.5975 18 4.873 (2.772–
8.128)
<0.0001
Ovary 6 2.113 (0.760–
4.792)
0.0732 13 2.842 (1.469–
5.053)
0.0002
Others EM 20 17.729 (9.951–
30.497)
<0.0001 45 24.822 (16.136–
38.119)
<0.0001
All 194 2.448 (2.099–
2.854)
<0.0001 466 3.781 (3.408–
4.195)
<0.0001
Statistical analysis was performed on all patients excluding those with TSHRAb. 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0122958.t003
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Association of specific thyroid disease with EM
When patients affected by thyroid disease were divided into 4 diagnostic groups, it was found
that only breast cancer and hematological malignancies had a significantly increased OR in all
categories of thyroid disease patients (Table 2). As regards other cancer types, melanoma asso-
ciated with NNTD, SN and MNTD; colorectal cancer with NNTD and MNTD; ovary cancer
with NNTD, MNTD and DTC; cancer of the uterus with SN, MNTD and DTC and kidney
cancer with MNTD and DTC (Table 2).
Thyroid autoantibodies and EM
Of the 6,386 patients, 2,369 (37.09%) were positive for TgAb, and/or TPOAb, and 197 (3.08%)
for TSHRAb, while the remaining 3,820 patients were negative. The 197 patients with TSHRAb
showed an increased risk of EM (OR 1.923, CI 1.004–3.375, p = 0.0206), compared to the gen-
eral population. In particular, among the patients affected by Graves’ disease 13 EM were re-
corded including neoplasms for breast (n = 7), colon (n = 2), kidney (n = 1), uterus (n = 1),
ovary (n = 1) and hematological malignancy (n = 1). Given the low number of patients and the
paucity of the EM encountered, no further analyses were performed on this group. Patients
with TgAb and/or TPOAb revealed an increased risk for melanoma, breast cancer and hemato-
logical malignancies (Table 3). On the other hand, patients negative for thyroid autoantibodies
presented an increased risk of all types of EM (Table 3). Finally, the OR for breast, colorectal,
uterus and kidney cancers were significantly lower in thyroid autoantibody positive patients,
with respect to the negative ones (Table 4).
Fig 1. Odd ratio of various primary extra-thyroidal malignancies at different ages in 6,389 female
patients affected by benign or malignant thyroid diseases.
doi:10.1371/journal.pone.0122958.g001
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Discussion
Epidemiological studies aimed at defining the association of thyroid disease with extra-thyroi-
dal malignancies (EM) have led to considerable interest in the possibility of revealing common
genetic and environmental factors underlying disease aetiology and progression [10–23]. In
particular, a number of different studies have highlighted the association between thyroid can-
cers and other primary EM, including cancers of the oral cavity, pharynx, salivary gland, stom-
ach, colorectum, breast, ovary, uterus, kidney, brain, adrenal gland, non-Hodgkin lymphoma,
and leukaemia, occurring either before or after diagnosis of thyroid cancer [10–22]. Regarding
the risk of EM in benign thyroid disease, few and conflicting results have been reported, mainly
regarding breast cancer [23–25]. This prompted us to analyze the relationship of EM not only
with malignant thyroid disease, but also with benign thyroid disease. Furthermore, these asso-
ciations were evaluated independently of the timing of thyroid disease diagnosis, because most
thyroid disease, including carcinomas, are characterized by a slow progression that may take
years to become clinically manifest and, hence, diagnosed. Moreover, this agrees with the
Ronckers and colleagues [20] report demonstrating that the association between thyroid cancer
and EM exists regardless of which cancer occurred first. Our results demonstrated that women
affected by thyroid disease, considered as a whole, have an increased risk of EM (OR 3.21)
compared to the general female population. Breast cancer was the most frequent EM observed,
and the highest OR was found for hematological malignancies (OR 8.5), followed by melanoma
(OR 6.7) and breast (OR 3.9) cancers. Age-matched analysis demonstrated that the highest OR
(11.3) for EM occurred at an early age (0–44 yr), to decline at an older age. By dividing patients
into four diagnostic categories (i.e. NNTD, SN, MNTD, and DTC), we observed that patients
affected by non-malignant thyroid disease have an increased risk for EM. In particular, while
melanoma and colorectal cancer associate with benign thyroid disease only, breast cancer and
hematological malignancies associated with both benign and malignant thyroid disease. As re-
gards DTC, our data confirm previous observations showing a significant relationship between
DTC and hematological malignancies, kidney, ovary, uterus and breast cancers [10–22].
It has been suggested that the long-term carcinogenic effects of specific cancer treatments
might be responsible for a second primary cancer. To this regard, several studies evaluating I131
treatment in thyroid cancer patients as a possible cause of increased risk of second primary EM
have produced conflicting results [14–22]. In particular, in some studies a 30–42% increased
Table 4. Differences in the Prevalence of Extra-Thyroidal Malignancies in Patients Positive (n = 2,369) or Negative (n = 3,820) for TgAb and/or
TPOAb.
Number of EM
Extra-thyroidal malignancies TgAb and/or TPOAb positive TgAb and TPOAb negative Odds ratio (95% CI) P value
Breast 102 246 0.654 (0.511–0.832) 0.0004
Colorectal 15 45 0.535 (0.276–0.980) 0.0335
Melanoma 19 35 0.874 (0.471–1.576) 0.6387
Hematological 21 28 1.211 (0.652–2.516) 0.5079
Uterus 9 36 0.401 (0.170–0.850) 0.0114
Kidney 2 18 0.178 (0.020–0.745) 0.0062
Ovary 6 13 0.744 (0.231–2.100) 0.3642
Others EM 20 45 0.714 (0.398–1.238) 0.2106
All 194 466 0.642 (0.536–0.768) <0.0001
Statistical analysis has been performed on all the patients excluding those with TSHRAb. 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0122958.t004
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risk of second primary malignancy attributed to I131 treatment has been reported, while in dif-
ferent studies no correlation between the exposure to I131 treatment and second primary malig-
nancies could be appreciated [16–18, 20, 21]. Whether anticancer treatments of EM, in
particular external beam radiation, may cause second primary thyroid cancers is also a matter
of debate (11–13, 20]. The observations reported here regarding the association of EM not only
with thyroid cancer but also with benign thyroid disease seem to suggest that factors other than
oncologic treatment may play a role in the initiation and progression of second primary malig-
nancies. In this context, the association of benign thyroid disease with breast cancer has been
extensively investigated, although the findings have proven controversial [23–25]. An earlier
meta-analysis by Sarlis and colleagues [24] found no association between autoimmune thyroid
disease and breast cancer. More recently, 28 studies were reviewed in a meta-analysis by Harde-
feldt and colleagues [23] showing an increased risk of breast cancer in patients with autoim-
mune thyroid disease. We recently showed that the OR for breast cancer increased in both
thyroid autoantibody positive and negative patients [25]. However, the OR was significantly
lower in thyroid autoantibody positive patients, compared to negative ones [25]. These results
are confirmed in the present study performed on larger case series. In addition, we showed
here that while thyroid autoantibody negative patients had an increased OR for all EM ana-
lyzed, in TgAb and/or TPOAb positive patients a significant increase in the OR was found only
for breast cancer, melanoma and hematological malignancies. This is in agreement with previ-
ous findings showing that the development of thyroid autoimmunity in cancer patients receiv-
ing immunotherapy is associated with better outcome [33]. Taken on the whole, these
observations indicate a protective role of thyroid autoantibodies versus EM, and support the
clinical evidence that breast cancer patients positive for TPOAb have better disease-free inter-
val and overall survival [23–25, 34]. Finally, in agreement with previous studies, we demon-
strated an increased risk of EM in TSHRAb positive patients [26, 35].
The molecular links between thyroid disease and breast cancer remain unidentified, and dif-
ferent explanations have been proposed, such as the promoter role of sodium/iodide sympor-
ter, as expressed in both breast and thyroid tissues, or the presence of progesterone and
estrogen receptors identified in the cytosol of tumor thyroid tissue, but not in normal tissue
[36–42]. In addition, it has been documented that: i) the expression of thyroid hormone (TH)
receptors is deregulated in primary and metastatic breast cancer cells; ii) TH may bind and ac-
tivate the estrogen receptor in breast cancer cells; iii) TH level positively correlates with breast
cancer risk; iv) TH affect estrogen production as well as estrogen receptor levels [36–42]. Based
on this evidence, it may be speculated that at an earlier age, where the association between thy-
roid disease and breast cancer is highest (OR 18.8), estrogens and TH may act in concert to
promote breast cancer progression. On the contrary, in older women, low-levels of free T4 rep-
resent an independent risk factor for breast cancer and this was confirmed by the finding that
levothyroxine treatment improves overall survival [43, 44].
In conclusion, we demonstrated that women affected by both benign and malignant thyroid
diseases, especially at a younger age and in absence of thyroid autoimmunity, have an increased
risk of developing primary extra-thyroidal malignancies, thus requiring a very careful follow-
up and surveillance. These observations should warrant the creation of regional and/or nation-
al registries to confirm these findings and to facilitate the identification of common genetic and
environmental factors underlying such disease associations.
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